Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells
Anna K. Nowak,Richard A. Lake,Amanda L. Marzo,Amanda L. Marzo,Bernadette Scott,Bernadette Scott,William R. Heath,Edward J. Collins,Jeffrey A. Frelinger,Bruce W. S. Robinson +9 more
Reads0
Chats0
TLDR
T tumor cell apoptosis in vivo neither sequesters tumor Ags nor cross-tolerizes tumor-specific CD8 cells, which has fundamental consequences for the development of tumor immunotherapy protocols and for understanding T cell reactivity to tumors and the in vivo immune responses to apoptotic cells.Abstract:
Cross-presentation of cell-bound Ags from established, solid tumors to CD8 cells is efficient and likely to have a role in determining host response to tumor. A number of investigators have predicted that when tumor Ags are derived from apoptotic cells either no response, due to Ag "sequestration," or CD8 cross-tolerance would ensue. Because the crucial issue of whether this happens in vivo has never been addressed, we induced apoptosis of established hemagglutinin (HA)-transfected AB1 tumors in BALB/c mice using the apoptosis-inducing reagent gemcitabine. This shrank the tumor by approximately 80%. This induction of apoptosis increased cross-presentation of HA to CD8 cells yet neither gross deletion nor functional tolerance of HA-specific CD8 cells were observed, based on tetramer analysis, proliferation of specific CD8 T cells, and in vivo CTL activity. Interestingly, apoptosis primed the host for a strong antitumor response to a second, virus-generated HA-specific signal in that administration of an HA-expressing virus after gemcitabine administration markedly decreased tumor growth compared with viral administration without gemcitabine. Thus tumor cell apoptosis in vivo neither sequesters tumor Ags nor cross-tolerizes tumor-specific CD8 cells. This observation has fundamental consequences for the development of tumor immunotherapy protocols and for understanding T cell reactivity to tumors and the in vivo immune responses to apoptotic cells.read more
Citations
More filters
Journal ArticleDOI
How dying cells alert the immune system to danger
Hajime Kono,Kenneth L. Rock +1 more
TL;DR: Current knowledge of cell death and repair processes in the host and their importance to host defence and disease pathogenesis has only been appreciated relatively recently is reviewed.
Journal ArticleDOI
Immunological aspects of cancer chemotherapy.
Laurence Zitvogel,Lionel Apetoh,Lionel Apetoh,François Ghiringhelli,Guido Kroemer,Guido Kroemer +5 more
TL;DR: It is proposed that future successes in the fight against cancer will rely on the development and clinical application of combined chemo- and immunotherapies.
Journal ArticleDOI
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death.
Noelia Casares,Marie O. Pequignot,Antoine Tesniere,François Ghiringhelli,Stephan Roux,Nathalie Chaput,Elise Schmitt,Ahmed Hamaï,Sandra Hervas-Stubbs,Michel Obeid,Fréderic Philippe Coutant,Didier Métivier,Evelyne Pichard,Pierre Aucouturier,Gérard Pierron,Carmen Garrido,Laurence Zitvogel,Guido Kroemer +17 more
TL;DR: It is shown that even in the absence of any adjuvant, tumor cells dying in response to anthracyclins can elicit an effective antitumor immune response that suppresses the growth of inoculated tumors or leads to the regression of established neoplasia.
Journal ArticleDOI
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.
TL;DR: The tremendous clinical success of checkpoint blockers illustrates the potential of reestablishing latent immunosurveillance for cancer therapy, and their in-depth comprehension will facilitate the design of novel combinatorial regimens with improved clinical efficacy.
Journal ArticleDOI
Indoleamine 2,3-dioxygenase and tumor-induced tolerance.
David H. Munn,Andrew L. Mellor +1 more
TL;DR: Strategies to block Indoleamine 2,3-dioxygenase (IDO) might enhance the effectiveness of tumor immunotherapy.
References
More filters
Journal ArticleDOI
Tolerance, danger, and the extended family.
TL;DR: The possibility that the immune system does not care about self and non-self, that its primary driving force is the need to detect and protect against danger, and that it does not do the job alone, but receives positive and negative communications from an extended network of other bodily tissues is discussed.
Journal ArticleDOI
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
TL;DR: It is shown that human dendritic cells, but not macrophages, efficiently present antigen derived from apoptotic cells, stimulating class I-restricted CD8+ CTLs, suggesting a mechanism by which potent APCs acquire antigens from tumours, transplants, infected cells, or even self-tissue, for stimulation or tolerization of C TLs.
Journal ArticleDOI
Mechanisms of cancer drug resistance
TL;DR: The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anti-cancer drugs from cells, but other mechanisms of resistance including insensitivity to drug-induced apoptosis and induction of drug-detoxifying mechanisms probably play an important role in acquired anticancer drug resistance as mentioned in this paper.
Journal ArticleDOI
Determination of lymphocyte division by flow cytometry
TL;DR: A new technique in which an intracellular fluorescent label is divided equally between daughter cells upon cell division is presented, applicable to in vitro cell division, as well as in vivo division of adoptively transferred cells, and can resolve multiple successive generations using flow cytometry.
Journal ArticleDOI
Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
TL;DR: Results indicate that CD8+ DCs play an important role in the generation of cytotoxic T lymphocyte responses specific for cell-associated antigens, suggesting an endosome to cytosol transport.
Related Papers (5)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid,Antoine Tesniere,Antoine Tesniere,Antoine Tesniere,François Ghiringhelli,François Ghiringhelli,François Ghiringhelli,Gian Maria Fimia,Lionel Apetoh,Lionel Apetoh,Lionel Apetoh,Jean-Luc Perfettini,Jean-Luc Perfettini,Jean-Luc Perfettini,Maria Castedo,Maria Castedo,Maria Castedo,Grégoire Mignot,Grégoire Mignot,Grégoire Mignot,Theoharis Panaretakis,Theoharis Panaretakis,Theoharis Panaretakis,Noelia Casares,Noelia Casares,Noelia Casares,Didier Métivier,Didier Métivier,Didier Métivier,Nathanael Larochette,Nathanael Larochette,Nathanael Larochette,Peter van Endert,Peter van Endert,Fabiola Ciccosanti,Mauro Piacentini,Laurence Zitvogel,Laurence Zitvogel,Laurence Zitvogel,Guido Kroemer,Guido Kroemer,Guido Kroemer +41 more
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Lionel Apetoh,François Ghiringhelli,Antoine Tesniere,Antoine Tesniere,Antoine Tesniere,Michel Obeid,Michel Obeid,Michel Obeid,Carla Ortiz,Carla Ortiz,Carla Ortiz,Alfredo Criollo,Alfredo Criollo,Alfredo Criollo,Grégoire Mignot,Grégoire Mignot,Grégoire Mignot,M. Chiara Maiuri,Evelyn Ullrich,Evelyn Ullrich,Evelyn Ullrich,Patrick Saulnier,Huan Yang,Sebastian Amigorena,Bernard Ryffel,Franck J. Barrat,Paul Saftig,Francis Lévi,Francis Lévi,Rosette Lidereau,Catherine Noguès,Jean-Paul Mira,Agnès Chompret,Virginie Joulin,Françoise Clavel-Chapelon,Jean Bourhis,Fabrice Andre,Suzette Delaloge,T. Tursz,Guido Kroemer,Guido Kroemer,Guido Kroemer,Laurence Zitvogel +42 more
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death.
Noelia Casares,Marie O. Pequignot,Antoine Tesniere,François Ghiringhelli,Stephan Roux,Nathalie Chaput,Elise Schmitt,Ahmed Hamaï,Sandra Hervas-Stubbs,Michel Obeid,Fréderic Philippe Coutant,Didier Métivier,Evelyne Pichard,Pierre Aucouturier,Gérard Pierron,Carmen Garrido,Laurence Zitvogel,Guido Kroemer +17 more